Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheoklong Ng

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Scientific Reports|April 17, 2026
Three large language models demonstrate competitive performance in Traditional Chinese Medicine national medical licensing examinations over two yearsChenghan Du, Yien Pan, Cheoklong Ng, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective studyXi Zhong, Tingxuan Huang, Yulu Peng, et al.
The Journal of Urology|March 18, 2025
Reply by AuthorsJiwei Huang, Xingyun Cai, Cheoklong Ng, et al.
The Journal of Urology|February 25, 2025
A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial CarcinomaJiwei Huang, Xingyun Cai, Cheoklong Ng, et al.
The Journal of Urology|March 14, 2025
Reply by AuthorsJiwei Huang, Xingyun Cai, Cheoklong Ng, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Clinical Genitourinary Cancer|May 10, 2025
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell CarcinomaCheoklong Ng, Cheng Peng, Shangqian Wang, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Scientific Reports|April 17, 2026
Three large language models demonstrate competitive performance in Traditional Chinese Medicine national medical licensing examinations over two yearsChenghan Du, Yien Pan, Cheoklong Ng, et al.
Cancer Immunology, Immunotherapy : CII|January 27, 2026
First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective studyXi Zhong, Tingxuan Huang, Yulu Peng, et al.
The Journal of Urology|March 18, 2025
Reply by AuthorsJiwei Huang, Xingyun Cai, Cheoklong Ng, et al.
The Journal of Urology|February 25, 2025
A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial CarcinomaJiwei Huang, Xingyun Cai, Cheoklong Ng, et al.
The Journal of Urology|March 14, 2025
Reply by AuthorsJiwei Huang, Xingyun Cai, Cheoklong Ng, et al.
Cancer Immunology, Immunotherapy : CII|September 13, 2025
The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world studyCheoklong Ng, Taile Jing, Shicheng Yu, et al.
Clinical Genitourinary Cancer|May 10, 2025
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell CarcinomaCheoklong Ng, Cheng Peng, Shangqian Wang, et al.
Pageof 1